Advanced glycation end products and bone loss during aging. - Wikidata - awgldk - TriplyDB

Advanced glycation end products and bone loss during aging.

Advanced glycation end products and bone loss during aging.

http://www.wikidata.org/entity/Q46613220

about

Aging of blood can be tracked by DNA methylation changes at just three CpG sites Does accumulation of advanced glycation end products contribute to the aging phenotype?Bone composition: relationship to bone fragility and antiosteoporotic drug effects Advanced glycation end products play adverse proinflammatory activities in osteoporosis Advanced Glycation End Products, Diabetes, and Bone Strength Heterogeneous glycation of cancellous bone and its association with bone quality and fragility Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study.Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease.In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption.Biochemical characterization of major bone-matrix proteins using nanoscale-size bone samples and proteomics methodology.Age-related changes in the plasticity and toughness of human cortical bone at multiple length scales.Effects of non-enzymatic glycation on cancellous bone fragility.Non-enzymatic glycation alters microdamage formation in human cancellous bone.Dietary advanced glycation end products and aging.Bone fragility in type 2 diabetes mellitus.Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone Association between non-enzymatic glycation, resorption, and microdamage in human tibial cortices.RAGE Deficiency Impairs Bacterial Clearance in Murine Staphylococcal Sepsis, but Has No Significant Impact on Staphylococcal Septic Arthritis A direct role of collagen glycation in bone fracture.Advanced Glycation End Products Affect Osteoblast Proliferation and Function by Modulating Autophagy Via the Receptor of Advanced Glycation End Products/Raf Protein/Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase/Extrac Multiscale Predictors of Femoral Neck In Situ Strength in Aging Women: Contributions of BMD, Cortical Porosity, Reference Point Indentation, and Nonenzymatic Glycation.Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties.Tuning three-dimensional collagen matrix stiffness independently of collagen concentration modulates endothelial cell behavior Protein carbamylation is a hallmark of aging Advanced Glycation End-products and Bone Fractures Advanced glycation and lipoxidation end products--amplifiers of inflammation: the role of food.Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes.Bone metabolism and fracture risk in type 2 diabetes mellitus.Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis.Pentosidine and increased fracture risk in older adults with type 2 diabetes.Aging is not a disease: distinguishing age-related macular degeneration from aging.Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.The contribution of collagen crosslinks to bone strength.Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers.Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology.Diabetes, collagen, and bone quality.Collagen modifications in postmenopausal osteoporosis: advanced glycation endproducts may affect bone volume, structure and quality.Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease.

P2860

Q21183983-3DE0E136-BCC1-4D8B-9441-2FC9B14A12A8 Q24632710-2C6C4396-1D2C-44FE-832E-74D285895333 Q26863596-2F1939A8-9550-48B2-A4FA-8AE7768A5A62 Q27024641-2E860652-F41C-4CAB-B897-D0DB8239F05C Q28076977-87A5167B-3B05-41A6-91AB-0069D2A1DAE8 Q28482286-E9027F55-C92B-4934-A262-0A55F6A29120 Q30578167-CAC69869-F94F-43AA-821F-B2F759DA60E4 Q33727902-0CE357D9-FF28-45EF-99FE-2B2F4ABEC48A Q33885263-B47A3462-9DD0-4AD9-80A3-A7508CCBE95A Q33909788-B1671841-D328-4324-A8BF-FD1EE4F81EB8 Q34004460-8A421172-6BE9-45AB-882E-D215F2E05905 Q35429093-0C418F1D-34DE-4C71-9C6A-513EC5608E43 Q35429148-8290201E-43F2-4DDF-8502-AD6A2A35964C Q35670859-93062D12-FAE1-4BF3-8965-A58042F8AD01 Q35825346-963052E8-C79F-4CDA-9DF4-0400E9AC608B Q35963018-C377011B-0E83-4B5D-85E7-364998328E49 Q35997620-712C410C-C158-4694-975E-983EE38DE834 Q36010491-D117B83A-DF10-472D-B00A-5937308384B7 Q36209840-D9544C04-35F6-4059-9B46-1CE93E032015 Q36296930-D3B5B564-FFFB-4BA9-BC01-4153E932D962 Q36301271-4235FC10-AD08-4E7B-A46E-DABC358FB519 Q36355576-6EACF93D-DED1-45B3-B489-7D32A15A0866 Q36372679-68488590-AE74-4925-97DB-87AA05B2E69A Q36428268-5CCB7FD2-D446-41A2-A9D0-ECEFAADA62C9 Q36563327-65F878A6-D1C3-458E-ADA0-2DDF5C14EE53 Q36868071-434D03D5-F4C5-4807-BB71-E73FCEDB4B01 Q36915810-AC247D91-E91A-443D-85F5-1275A24179E7 Q36965274-923DDA39-3D96-49B5-A10C-1134FE8B606C Q37056305-83697DC9-D0A2-4386-9992-20E67FE19331 Q37119404-60E4F4DD-7485-42BB-9DE9-879E2BC93C54 Q37257534-898397AD-54DA-432E-9C6A-F2A71FC76192 Q37315838-FF647A53-BEEC-4AFD-99F7-2D21880B5AE8 Q37323596-C00EFF63-9D22-4E0F-A6A1-22258E4BDE33 Q37404948-E0707CBD-D142-4178-9D42-2E11E5DDFA20 Q37649859-4B7A58E1-77FB-4F3A-AC8B-C1B4BBB7D984 Q37673039-7F05EE9E-5CD5-4BE0-B382-4686BFF11461 Q38108373-8E5DE591-0F29-48E1-8582-FFAB52D3FC06 Q38195566-3A9DE493-5087-4AF0-A4EF-EF3D12229C5C Q38216337-1AAA36B6-CBC1-4CE1-B6E4-9065D29CB40F Q38384409-3D9D2FE6-4666-493E-9242-01DE54ABD501

P2860

Advanced glycation end products and bone loss during aging.

http://www.wikidata.org/entity/Q46613220

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Advanced glycation end products and bone loss during aging.

@en

Advanced glycation end products and bone loss during aging.

@nl

type

label

Advanced glycation end products and bone loss during aging.

@en

Advanced glycation end products and bone loss during aging.

@nl

prefLabel

Advanced glycation end products and bone loss during aging.

@en

Advanced glycation end products and bone loss during aging.

@nl

P1433

Q46613220-D66ADA3D-D731-4FDB-B9A5-9728D12BF5D7

P1476

Q46613220-DADFC95B-B803-4E4A-8AD7-8275E4710E9B

P2093

Q46613220-36FA860C-80AF-4F10-BE5A-44836912DD6D

Q46613220-495988EF-A300-4EA6-8938-2C4DB5BAC502

Q46613220-663946BD-9216-4ADA-8811-4117C4C0504E

Q46613220-BC9ACF0E-7BD2-401F-BA43-730A64691B7C

Q46613220-C349FAE1-9419-4C74-BCF1-4DF78B7A4F35

P2860

Q46613220-06A08CEE-0367-48D5-A551-9F9C814E429B

Q46613220-0BC4FE6E-66B7-4F0F-B490-5C64CC2AE8C2

Q46613220-0CFDB4FF-61AC-442F-A3EC-A22F77726892

Q46613220-209F1FFF-E3DB-4349-86C6-825E4547B387

Q46613220-35B524B9-85F6-406B-89FB-B0B790729E0A

Q46613220-381FBA38-A484-4EFC-BAA8-A80FF395BCFE

Q46613220-9B5B4B01-EAC6-4FF4-93D9-46AED0BF3680

Q46613220-AEBFB5FE-D0CC-43E2-9A66-93E2BA220C4A

Q46613220-B4FCCEF4-2C84-47DB-BA28-C435EAC3C538

Q46613220-B705B1FC-0944-4257-B07A-15820A20ACDA

P304

Q46613220-CCD9D0E3-AED4-46D1-A45F-78662238FDC5

P31

Q46613220-FE93D5EA-9B0C-40C5-9DA5-22ED6C2E6C67

P356

Q46613220-7A113D56-3525-4E04-BE76-0DAB060EF98A

P478

Q46613220-97E1010E-E98B-4AB6-9B6A-23B0B24411D5

P50

Q46613220-5FA06683-FBB6-425A-A490-4D7B5558558C

Q46613220-DFEA131A-4D13-4829-A948-31DEA60AC26C

P577

Q46613220-11F1C95B-AC75-45CD-91B9-AE982299E8BC

P698

Q46613220-534D992F-41DE-41F6-A717-88D5EE17FD35

P356

ANNALS.1333.082

P1433

Annals of the New York Academy of Sciences

P1476

Advanced glycation end products and bone loss during aging

@en

P2093

Alberto Federici

http://www.w3.org/2001/XMLSchema#string

Alessia Poggi

http://www.w3.org/2001/XMLSchema#string

Marcello Federici

http://www.w3.org/2001/XMLSchema#string

Maria Cirnigliaro

http://www.w3.org/2001/XMLSchema#string

Simona Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress

Role of the Maillard reaction in diabetes mellitus and diseases of aging.

Influence of nonenzymatic glycation on biomechanical properties of cortical bone.

Osteoporosis, genetics and hormones.

Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence.

Pathogenesis of osteoporosis and challenges for drug delivery.

The osteoblast: a sophisticated fibroblast under central surveillance.

End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen

The worldwide problem of osteoporosis: insights afforded by epidemiology.

The AGE of the matrix: chemistry, consequence and cure.

P304

710-717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1196/ANNALS.1333.082

http://www.w3.org/2001/XMLSchema#string

P478

1043

http://www.w3.org/2001/XMLSchema#string

P50

Fiammetta Monacelli

Patrizio Odetti

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16037297

http://www.w3.org/2001/XMLSchema#string